Introduction {#s1}
============

Asthma is a complex, persistent, inflammatory disease characterized by airway hyper-responsiveness and inflammation. Asthma currently represents a major public health burden in many countries [@pone.0069120-Masoli1]. Thus an understanding of the causes of this disease is an area of intense interest. Cumulative evidence supports an important genetic role in determining asthma risk [@pone.0069120-Laitinen1].

T helper-2 (Th2) cytokines, such as interleukin-4 (IL-4) and IL-13, play central roles in allergic inflammation and asthma. They exert their biological activities by binding to their respective cell surface receptors, both of which share the α chain of the IL-4 receptor (IL-4Rα) [@pone.0069120-Miloux1]. Kotsimbos et al. [@pone.0069120-Kotsimbos1] showed that expression levels of IL-4Rα messenger RNA and protein were significantly increased in the epithelium and subepithelium of biopsy specimens from subjects with atopic asthma, compared with atopic control subjects. Additionally, IL-4Rα-deficient mice were unable to produce immunoglobulin E (IgE) and the Th2 inflammatory reaction was markedly diminished [@pone.0069120-NobenTrauth1]. Furthermore, IL-4Rα-targeted antibodies could reduce lung inflammation, airway hyper-­responsiveness and goblet-cell hyperplasia in mouse models of asthma [@pone.0069120-Perkins1]. Therefore, these results indicated that IL-4Rα may play an important role in the pathogenesis of asthma and suggested that *IL4RA* may be a strong candidate gene for asthma susceptibility.

*IL4RA* is located on chromosome 16p12.1. Many studies have investigated the associations between the *IL4RA* polymorphisms and susceptibility to asthma [@pone.0069120-Mitsuyasu1]--[@pone.0069120-Su1]. Most of these studies focused on two polymorphisms: I50V (rs1805010) and Q551R (rs1801275). However, the results of these studies have been controversial and inconclusive. A single study may not have sufficient power to detect slight effects of these polymorphisms on asthma because of relatively small sample sizes; however, a meta-analysis may provide more credible evidence by systematically summarizing the existing data. In 2007, Loza and Chang conducted a meta-analysis and concluded that the *IL-4RA* Q551R polymorphism, but not the I50V polymorphism, was associated with asthma risk [@pone.0069120-Loza1]. However, that meta-analysis only included 13 studies, and several new studies with more data have been published since 2007. We therefore conducted an up-to-date meta-analysis to re-investigate the association between *IL4RA* polymorphisms and asthma risk.

Methods {#s2}
=======

Publication search {#s2a}
------------------

A literature search of the PubMed, Embase, Chinese National Knowledge Infrastructure (CNKI), and Wanfang databases was conducted for studies published before February 2013 using combinations of the following terms: (asthma or asthmatic) and (interleukin-4 receptor α chain or IL-4Rα or IL4Rα or IL4RA) and (polymorphism or mutation or variant). All eligible articles were retrieved, and their references were checked for other relevant studies.

Study selection {#s2b}
---------------

All selected studies complied with the following three criteria: (1) evaluation of the *IL4RA* I50V and Q551R polymorphisms and asthma risk; (2) using a case-control design; and (3) genotype distributions in both cases and controls available for estimating an odds ratio (OR) with a 95% confidence interval (CI). If serial studies of the same population from the same group were reported, the largest study was included.

Data extraction {#s2c}
---------------

Two investigators (Nie and Chen) independently extracted data from the included studies. The following information was collected from each study: first author\'s name, year of publication, original country, ethnicity, age group, atopic status, sample size, and genotype number in cases and controls. We verified the accuracy of the data by comparing collection forms between investigators. If different results were generated, the full text of the article was checked.

Qualitative assessment {#s2d}
----------------------

The quality of included studies was assessed independently by two investigators (Nie and Chen).[**Table** **S1**](#pone.0069120.s007){ref-type="supplementary-material"} shows the criteria for quality appraisal. The quality scoring system was based on traditional epidemiological considerations and asthma genetic issues [@pone.0069120-Thakkinstian1]. The criteria covered the representativeness of cases and controls, the ascertainment of cases and controls, genotyping examination, Hardy-Weinberg equilibrium (HWE), and association assessment. Scores ranged from the lowest zero to the highest thirteen.

Statistical analysis {#s2e}
--------------------

A meta-analysis was performed when data from at least three similar studies were available. The strengths of the associations between the *IL4RA* polymorphisms and asthma risk were measured by ORs and 95% CIs. The statistical significance of summary OR was determined using the *Z* test. OR1, OR2, and OR3 were calculated for the genotypes: 1). II vs. VV (OR1), IV vs. VV (OR2), and II vs. IV (OR3) for the I50 V polymorphism, 2). RR vs. QQ (OR1), QR vs. QQ (OR2), and RR vs. QR (OR3) for the Q551R polymorphism. These pairwise differences were used to indicate the most appropriate genetic model [@pone.0069120-Thakkinstian2]--[@pone.0069120-Nie4]. Once the best genetic model was identified, this model was used to collapse the three genotypes into two groups (except in the case of a co-dominant model) and to pool the results.

HWE was evaluated using the Chi-square test. *P*\<0.05 was considered representative of a departure from HWE. Heterogeneity of effects across studies was assessed using the Chi-square statistic and quantified by *I^2^*, which represented the percentage of total variation across studies that was attributable to heterogeneity rather than chance (*P*\<0.10 was considered representative of statistically significant heterogeneity). A fixed-effect model was used when there was no heterogeneity in the studies. Otherwise, the random-effect model was used. Subgroup analyses were performed by stratifying according to ethnicity, age group, and atopic status. The stability of the results was assessed by performing a sensitivity analysis using sequential omission of individual studies. A cumulative meta-analysis was conducted by undertaking sequential pooling, starting with the earliest studies. Funnel plots were performed to estimate the potential publication bias, with an asymmetrical plot suggesting a possible publication bias. The asymmetry was assessed using the Egger\'s linear regression test and *P*\<0.05 was considered to represent statistically significant publication bias [@pone.0069120-Egger1]. All statistical tests were performed using STATA 11.0 software (Stata Corporation, College Station, TX). The Bonferroni correction of critical *P* values for two genetic models was applied when performing a high number of comparisons.

Results {#s3}
=======

Study characteristics {#s3a}
---------------------

Fifty studies met the inclusion criteria [@pone.0069120-Mitsuyasu1]--[@pone.0069120-Su1]. A flowchart detailing the process for study identification and selection is shown in [**Figure 1**](#pone-0069120-g001){ref-type="fig"} **.** A study by Undarmaa et al. [@pone.0069120-Undarmaa1] presented two independent case-control studies, each of which was considered separately for analysis. There were 33 studies of the I50V polymorphism and 35 36 studies of the Q551R polymorphism. Twenty-seven studies were performed in Asians, 19 in Caucasians, two in Mexicans, and one in African Americans. Nineteen studies were performed in adults, and 21 in children. Twelve studies included atopic asthma patients and nine included both atopic and non-atopic asthma patients, but data for these patients could be extracted separately. The quality scores ranged from 5 to 11, suggesting that the methodological quality was generally acceptable. The characteristics of each study are presented in [**Table** **1**](#pone-0069120-t001){ref-type="table"}. Genotype frequencies and HWE examination results are listed in [**Table** **2**](#pone-0069120-t002){ref-type="table"}. Seven studies were not in HWE, and these studies were not included in the meta-analysis.

![Flow of study identification, inclusion, and exclusion.](pone.0069120.g001){#pone-0069120-g001}

10.1371/journal.pone.0069120.t001

###### Characteristics of the case-control studies included in meta-analysis.

![](pone.0069120.t001){#pone-0069120-t001-1}

  First author/                                                                                                                   Age                                     Atopic                   Case   Control     *IL4RA*    
  ----------------------------------------------- ------ ------------- ---------------------------------------- ---------------------------------------- ---------------------------------------- ------ --------- ------------- ----
  Mitsuyasu [@pone.0069120-Mitsuyasu1]             1998      Japan                      Asian                    Mixed[\*](#nt101){ref-type="table-fn"}   Mixed[\*](#nt101){ref-type="table-fn"}   360      120        I50V       7
  Mitsuyasu [@pone.0069120-Mitsuyasu2]             1999      Japan                      Asian                    Mixed[\*](#nt101){ref-type="table-fn"}   Mixed[\*](#nt101){ref-type="table-fn"}   300      100        Q551R      7
  Noguchi [@pone.0069120-Noguchi1]                 1999      Japan                      Asian                                    Mixed                                    Atopic                   101      101        I50V       9
  Rosa-Rosa [@pone.0069120-RosaRosa1]              1999       USA                     Caucasian                                  Adults                   Mixed[\*](#nt101){ref-type="table-fn"}   149      57         Q551R      7
  Heinzmann [@pone.0069120-Heinzmann1]             2000      Japan                      Asian                                    Adults                   Mixed[\*](#nt101){ref-type="table-fn"}   200      100        Q551R      8
  Sandford [@pone.0069120-Sandford1]               2000     Canada                    Caucasian                                  Adults                                     NA                     221      143        Q551R      10
  Takabayashi [@pone.0069120-Takabayashi1]         2000      Japan                      Asian                                   Children                                  Atopic                   100      100     I50V, Q551R   7
  Hakonarson [@pone.0069120-Hkonarson1]            2001     Iceland                   Caucasian                                  Mixed                                    Atopic                    94      94         Q551R      10
  Howard [@pone.0069120-Howard1]                   2002   Netherlands                 Caucasian                                  Adults                                     NA                     151      114     I50V, Q551R   9
  Leung [@pone.0069120-Leung1]                     2002      China                      Asian                                   Children                                    NA                      76      70         I50V       9
  Mújica-López [@pone.0069120-MujicaLopez1]        2002     Mexico                     Mexican                                  Children                                  Atopic                    30      32         I50V       6
  Risma [@pone.0069120-Risma1]                     2002       USA                     Caucasian                                  Adults                   Mixed[\*](#nt101){ref-type="table-fn"}   200      65      I50V, Q551R   7
  Beghe [@pone.0069120-Beghe1]                     2003       USA                     Caucasian                                  Mixed                                      NA                     186      670     I50V, Q551R   7
  Cui [@pone.0069120-Cui1]                         2003      China                      Asian                                    Mixed                                    Atopic                   241      175        Q551R      7
  Hytonen [@pone.0069120-Hytonen1]                 2004     Sweden                    Caucasian                                  Adults                                   Atopic                   170      100     I50V, Q551R   6
  Lee [@pone.0069120-Lee1]                         2004      Korea                      Asian                                   Children                  Mixed[\*](#nt101){ref-type="table-fn"}   256      100     I50V, Q551R   9
  Yang [@pone.0069120-Yang1]                       2004      China                      Asian                                    Adults                                     NA                      34      29         I50V       5
  Isidoro-García [@pone.0069120-IsidoroGarcia1]    2005      Spain                    Caucasian                                  Adults                   Mixed[\*](#nt101){ref-type="table-fn"}   133      79         Q551R      8
  Hu [@pone.0069120-Hu1]                           2005      China                      Asian                                   Children                                  Atopic                   175      175        Q551R      6
  Sun [@pone.0069120-Sun1]                         2005      China                      Asian                                   Children                                    NA                      82      59         Q551R      6
  Bernstein [@pone.0069120-Bernstein1]             2006       USA                     Caucasian                                  Adults                                     NA                      62      75      I50V, Q551R   9
  Kabesch [@pone.0069120-Kabesch1]                 2006     Germany                   Caucasian                                 Children                                    NA                      73      773        I50V       9
  Melen [@pone.0069120-Melen1]                     2006     Sweden                    Caucasian                                 Children                                    NA                     521      509     I50V, Q551R   7
  Deng [@pone.0069120-Deng1]                       2006      China                      Asian                                    Mixed                                      NA                     100      100        I50V       6
  Gui [@pone.0069120-Gui1]                         2006      China                      Asian                                   Children                                    NA                      50      50         Q551R      7
  Tang [@pone.0069120-Tang1]                       2006      China                      Asian                                    Mixed                                      NA                     103      62         I50V       5
  Battle [@pone.0069120-Battle1]                   2006       USA                  African American                              Mixed                                      NA                     264      176        I50V       11
  López [@pone.0069120-Lopez1]                     2007     Mexico                     Mexican                                  Children                                    NA                      88      88      I50V, Q551R   7
  Mak [@pone.0069120-Wang1]                        2007      China                      Asian                                    Adults                   Mixed[\*](#nt101){ref-type="table-fn"}   285      291        Q551R      9
  Zhang W [@pone.0069120-Zhang1]                   2007      China                      Asian                                    Adults                                     NA                     303      355     I50V, Q551R   8
  Zhang H [@pone.0069120-Zhang2]                   2007      China                      Asian                                    Mixed                                      NA                     423      114     I50V, Q551R   7
  Chan [@pone.0069120-Chan1]                       2008      China                      Asian                                   Children                                    NA                     295      167        I50V       9
  de Faria [@pone.0069120-DeFaria1]                2008     Brazil                      Mixed                                   Children                                  Atopic                    88      202        I50V       6
  Liu [@pone.0069120-Xiaomin1]                     2008      China                      Asian                                    Adults                                     NA                     108      88         Q551R      5
  Trajkov [@pone.0069120-Trajkov1]                 2008    Macedonia                  Caucasian                                  Adults                                     NA                      74      249        Q551R      8
  Sun [@pone.0069120-Sun2]                         2008      China                      Asian                                    Adults                                     NA                      82      50         Q551R      6
  Amirzargar [@pone.0069120-Amirzargar1]           2009      Iran                     Caucasian                                 Children                                    NA                      59      139        Q551R      8
  Llanes [@pone.0069120-Llanes1]                   2009      Spain                    Caucasian                                  Adults                                   Atopic                   109      50      I50V, Q551R   8
  Wang [@pone.0069120-Wang1]                       2009      China                      Asian                                   Children                                    NA                     449      512     I50V, Q551R   10
  Xu [@pone.0069120-Xu1]                           2009      China                      Asian                                   Children                                    NA                     128      82      I50V, Q551R   7
  Beghe [@pone.0069120-Beghe2]                     2010    UK Italy                   Caucasian                                  Adults                                   Mixed                    299      176     I50V, Q551R   9
  Berce [@pone.0069120-Berce1]                     2010    Slovenia                   Caucasian                                 Children                  Mixed[\*](#nt101){ref-type="table-fn"}   106      89         Q551R      8
  Bottema [@pone.0069120-Bottema1]                 2010   Netherlands                 Caucasian                                  Adults                                   Atopic                   118      102     I50V, Q551R   9
  Michel [@pone.0069120-Michel1]                   2010     German                    Caucasian                                 Children                                    NA                     703      658        I50V       11
  Undarmaa 1 [@pone.0069120-Undarmaa1]             2010      Japan                      Asian                                   Children                                  Atopic                   325      336     I50V, Q551R   9
  Undarmaa 2 [@pone.0069120-Undarmaa1]             2010      Japan                      Asian                                    Adults                                   Atopic                   367      676     I50V, Q551R   9
  Wu [@pone.0069120-Wu1]                           2010      China                      Asian                                   Children                                    NA                     252      227     I50V, Q551R   8
  Fan [@pone.0069120-Fan1]                         2010      China                      Asian                                    Adults                                     NA                      62      30         Q551R      5
  GeMDBJ [@pone.0069120-Genome1]                   2010      Japan                      Asian                                      NA                                       NA                     770     2375        Q551R      NA
  Murk [@pone.0069120-Murk1]                       2011       USA       Mixed[\*](#nt101){ref-type="table-fn"}                  Children                                  Atopic                    99      480     I50V, Q551R   7
  Su [@pone.0069120-Su1]                           2012      China                      Asian                                   Children                                    NA                     235     1075        I50V       10

Different data could be separately extracted.

NA, not available.

10.1371/journal.pone.0069120.t002

###### Distribution of *IL4RA* I50V and Q551R polymorphisms among patients and controls.

![](pone.0069120.t002){#pone-0069120-t002-2}

  Studies           Asthma   Control   HWE (*P* value)                     
  ---------------- -------- --------- ----------------- ----- ----- ------ -------
  Mitsuyasu          142       125           93          20    57     43    0.880
  Noguchi             10       57            34          16    44     41    0.470
  Takabayashi         17       49            34          16    36     48    0.048
  Howard              30       53            26          25    42     20    0.770
  Leung               23       38            15          19    35     16    0.988
  Mújica-López        15       13             2          19    11     2     0.811
  Risma               67       98            35          20    32     13    0.975
  Beghe               46       101           39          199   340   131    0.509
  Hytonen             28       49            23          29    51     20    0.777
  Lee                 54       133           69          20    51     29    0.777
  Yang                6        21             7           8    16     5     0.534
  Bernstein           24       29             9          19    43     13    0.182
  Kabesch             25       32            16          256   375   142    0.820
  Melen              169       256           96          148   253   108    0.995
  Deng                24       47            29           9    33     58    0.189
  Tang                33       36            34          18    23     21    0.044
  Battle              76       131           55          56    86     32    0.919
  López               29       42            17          34    47     15    0.852
  Zhang W             84       154           65          99    180    76    0.729
  Zhang H             78       168           106         17    53     44    0.873
  Chan                79       159           57          49    80     38    0.626
  de Faria            20       52            16          67    96     39    0.661
  Llanes              35       52            22          16    23     11    0.617
  Wang               139       201           105         136   250   124    0.667
  Xu                  50       54            24          18    43     21    0.649
  Beghe               84       149           66          51    88     37    0.933
  Bottema             34       59            25          30    51     21    0.937
  Michel             162       351           190         122   322   214    0.964
  Undarmaa 1         133       150           42          127   159    50    0.984
  Undarmaa 2         138       174           55          238   326   112    0.984
  Wu                  46       131           75          59    110    58    0.642
  Murk                28       49            23          142   236   106    0.670
  Su                  80       101           54          280   505   290    0.048
  *IL4RA* Q551R       RR       QR            QQ          RR    QR     QQ   
  Mitsuyasu           7        76            217          1    21     78    0.751
  Rosa-Rosa           19       49            81           1    20     36    0.339
  Heinzmann           16       80            104          5    34     61    0.926
  Sandford            7        69            145          5    43     95    0.961
  Takabayashi         2        27            71           5    16     79    0.003
  Hakonarson          3        28            63           4    37     57    0.505
  Howard              8        39            104          5    36     73    0.834
  Risma               19       84            97           3    20     42    0.765
  Beghe               11       62            114         36    229   404    0.635
  Cui                 23       89            129          4    41    130    0.720
  Hytonen             6        35            59           3    30     67    0.871
  Lee                 9        58            189          5    11     84    0.000
  Isidoro-García      1        41            91           4    26     49    0.820
  Hu                  19       66            90           4    41    130    0.720
  Sun                 4        19            59           3    10     46    0.033
  Bernstein           4        17            40           2    30     43    0.222
  Melen               28       184           309         25    174   310    0.927
  Gui                 2        15            33           2    14     34    0.716
  López               8        39            49           6    42     38    0.215
  Mak                 4        81            200          9    91    191    0.642
  Zhang W             19       87            197         22    93    240    0.003
  Zhang H             8        87            257          0    27     87    0.152
  Liu                 15       79            54           0    78     10    0.000
  Trajkov             3        27            44          11    78    212    0.262
  Sun                 2        15            65           0     8     42    0.539
  Amirzargar          1        25            32           2    30    106    0.941
  Llanes              3        37            69           2    14     34    0.716
  Wang                9        112           326         12    140   360    0.710
  Xu                  8        49            71           2    29     51    0.364
  Beghe               14       103           182          8    58    110    0.920
  Berce               6        28            72           6    27     56    0.285
  Bottema             7        43            68           7    41     54    0.835
  Undarmaa 1          7        73            245          8    86    242    0.913
  Undarmaa 2          12       102           253         10    154   512    0.681
  Wu                  8        61            183          4    55    168    0.837
  Fan                 6         8            48           3     2     25    0.000
  GeMDBJ              20       194           556         46    588   1741   0.655
  Murk                16       38            45          31    186   263    0.806

HWE, Hardy-Weinberg equilibrium.

Quantitative data synthesis {#s3b}
---------------------------

### *IL4RA* I50V polymorphism {#s3b1}

Thirty studies investigated the association between the I50V polymorphism and asthma risk. The total sample sizes for case and control groups were 6442 and 7240, respectively. The estimated OR1, OR2 and OR3 values were 1.14 (*P* = 0.08), 1.09 (*P* = 0.06), and 1.06 (*P* = 0.35), respectively ([**Table** **3**](#pone-0069120-t003){ref-type="table"}). These estimates suggested a dominant genetic model; therefore II and IV were combined and compared with VV. The pooled OR was 1.13 (95% CI 1.04--1.23, *P* = 0.005) ([**Figure** **2**](#pone-0069120-g002){ref-type="fig"}). There was no significant heterogeneity (*I^2^* = 5%, *P* = 0.38). In the stratified analysis by ethnicity, no significant association was found for the studies in Asians (OR = 1.23, 95% CI 1.05--1.45, *P* = 0.01) or Caucasians (OR = 1.10, 95% CI 0.96--1.26, *P* = 0.15). In the subgroup analysis by age, the *IL4RA* I50V polymorphism was not associated with pediatric asthma risk (OR = 1.15, 95% CI 1.03--1.29, *P* = 0.01) or adult asthma risk (OR = 1.08, 95% CI 0.91--1.27, *P* = 0.39). In the subgroup analysis according to atopic status, the *IL4RA* I50 V polymorphism was not significantly associated with the risk of atopic asthma (OR = 1.19, 95% CI 1.01--1.40, *P* = 0.04) or non-atopic asthma risk (OR = 0.92, 95% CI 0.63--1.35, *P* = 0.67).

![Meta-analysis for the association between asthma risk and the *IL4RA* I50V polymorphism.](pone.0069120.g002){#pone-0069120-g002}

10.1371/journal.pone.0069120.t003

###### Determination of the genetic effects of *IL4RA* polymorphisms on asthma and subgroup analysis.

![](pone.0069120.t003){#pone-0069120-t003-3}

                                Sample size   No. of   Test of association                       Heterogeneity                                 
  --------------- ------------ ------------- -------- --------------------- ------------------- --------------- ---------- --- ------- ------- ------
  *IL4RA* I50V                                                                                                                                 
  II vs. VV         Overall        3314        3707            29            1.14 (0.98--1.33)       1.76          0.08     R   51.82   0.006   44.0
  IV vs. VV         Overall        4564        5172            29            1.09 (1.00--1.20)       1.90          0.06     F   18.52   0.93    0.0
  II vs. IV         Overall        5006        5601            29            1.06 (0.94--1.19)       0.94          0.35     R   45.83   0.02    37.0
  II+IV vs. VV      Overall        6442        7240            29            1.13 (1.04--1.23)       2.78         0.005     F   30.63   0.38    5.0
  II+IV vs. VV       Asian         3394        2987            14            1.23 (1.05--1.45)       2.51          0.01     R   21.06   0.07    38.0
  II+IV vs. VV     Caucasian       2480        3265            11            1.10 (0.96--1.27)       1.44          0.15     F   5.71    0.84    0.0
  II+IV vs. VV      Children       3500        4366            15            1.15 (1.03--1.29)       2.46          0.01     F   16.56   0.28    15.0
  II+IV vs. VV       Adult         1821        1835            11            1.08 (0.91--1.27)       0.86          0.39     F   5.13    0.88    0.0
  II+IV vs. VV       Atopic        1919        2368            12            1.19 (1.01--1.40)       2.10          0.04     F   9.13    0.61    0.0
  II+IV vs. VV     Non-atopic       235        285              3            0.92 (0.63--1.35)       0.42          0.67     F   0.78    0.68    0.0
  *IL4RA* Q551R                                                                                                                                
  RR vs. QQ         Overall        4702        6144            32            1.46 (1.15--1.87)       3.05         0.002     R   44.54   0.05    30.0
  QR vs. QQ         Overall        6441        8326            32            1.11 (1.00--1.24)       1.92          0.05     R   53.54   0.007   42.0
  RR vs. QR         Overall        2357        2718            32            1.35 (1.12--1.63)       3.11         0.002     F   24.09   0.81    0.0
  RR vs. QR+QQ      Overall        6750        8594            32            1.46 (1.22--1.75)       4.14        \<0.0001   F   37.07   0.21    16.0
  RR vs. QR+QQ       Asian         3974        5263            14            1.72 (1.31--2.25)       3.91        \<0.0001   F   17.54   0.18    26.0
  RR vs. QR+QQ     Caucasian       2642        3185            17            1.09 (0.86--1.38)       0.71          0.48     F   11.96   0.75    0.0
  RR vs. QR+QQ      Children       2357        2784            12            1.50 (1.13--1.99)       2.78         0.005     F   14.21   0.22    23.0
  RR vs. QR+QQ       Adult         2749        2479            16            1.36 (1.00--1.84)       1.98          0.05     F   16.32   0.36    8.0
  RR vs. QR+QQ       Atopic        2533        2868            16            1.88 (1.27--2.79)       3.15         0.002     R   22.95   0.09    35.0
  RR vs. QR+QQ     Non-atopic       445        747              7            1.77 (0.97--3.23)       1.85          0.06     F   6.41    0.38    6.0

Bonferroni correction was applied (*P*\<0.00714). vs., versus; R, random-effects model; F, fixed-effects model; HWE, Hardy-Weinberg equilibrium.

Cumulative meta-analyses were conducted. A tendency toward significant association with asthma risk was found ([**Figure** **S1**](#pone.0069120.s001){ref-type="supplementary-material"}). We performed a sensitivity analysis to evaluate the stability of the meta-analysis. As shown in [**Figure** **S2**](#pone.0069120.s002){ref-type="supplementary-material"}, the statistical significance of the result was not altered when any single study was omitted. The funnel plot did not reveal evidence of obvious asymmetry ([**Figure** **S3**](#pone.0069120.s003){ref-type="supplementary-material"}). The result was further supported by Egger\'s test (*P* = 0.601).

### *IL4RA* Q551R polymorphism {#s3b2}

Thirty-two studies identified an association between the *IL4RA* Q551R polymorphism and asthma risk. A total of 6750 cases and 8594 controls were included in this meta-analysis. The estimated OR1, OR2 and OR3 values were 1.46 (*P* = 0.002), 1.11 (*P* = 0.05), and 1.35 (*P* = 0.002), respectively ([**Table** **3**](#pone-0069120-t003){ref-type="table"}). Thus, these estimates suggested a recessive genetic model; therefore QR and QQ were combined and compared with RR. The pooled OR was 1.46 (95% CI 1.22--1.75, *P*\<0.0001) ([**Figure** **3**](#pone-0069120-g003){ref-type="fig"}). No significant heterogeneity was observed (*I^2^* = 16%, *P* = 0.21). Subgroup analysis was performed by ethnicity. Statistically significant findings were found in Asians (OR = 1.72, 95% CI 1.31--2.25, *P*\<0.0001) but not in Caucasians (OR = 1.09, 95% CI 0.86--1.38, *P* = 0.48). In the stratified analysis by age group, a statistically significantly increased asthma risk was found among children (OR = 1.50, 95% CI 1.13--1.99, *P* = 0.005), but no significant risk was found among adult asthmatic patients (OR = 1.36, 95% CI 1.00--1.84, *P* = 0.05). In terms of atopic status, we found a significant association between this polymorphism and atopic asthma risk (OR = 1.88, 95% CI 1.27--2.79, *P* = 0.002). However, there was no significant association with non-atopic asthma (OR = 1.90, 95% CI 0.94--3.84, *P* = 0.07).

![Meta-analysis for the association between asthma risk and the *IL4RA* R551Q polymorphism.](pone.0069120.g003){#pone-0069120-g003}

Evidence from a cumulative meta-analysis showed that the results were consistent over time ([**Figure** **S4**](#pone.0069120.s004){ref-type="supplementary-material"}). A sensitivity analysis showed no substantial modification of the estimates after exclusion of individual studies ([**Figure** **S5**](#pone.0069120.s005){ref-type="supplementary-material"}). The shape of the funnel plot was symmetrical ([**Figure** **S6**](#pone.0069120.s006){ref-type="supplementary-material"}). Egger\'s test indicated the absence of publication bias (*P* = 0.773).

Discussion {#s4}
==========

On the basis of 50 eligible case-control studies, this meta-analysis comprehensively evaluated the association between the *IL4RA* I50V and Q551R polymorphisms and asthma risk. In terms of the *IL4RA* I50 V polymorphism, we found that individuals with the 50I allele (II or IV) showed an increased risk of asthma in the overall population. However, in the subgroup analyses based on ethnicity, age group, and atopic status, no significant associations were observed after Bonferroni correction. A significant association was also noted for the *IL4RA* Q551R polymorphism. This result suggests that individuals carrying the RR genotype had an increased asthma risk. There is no significant difference in the frequencies of *IL4RA* Q551R alleles between Asians and Caucasians with asthma (<http://asia.ensembl.org>); however, analysis stratified by ethnicity showed a significant association with asthma in Asians, but not in Caucasians. It is possible that different lifestyles, diets, and environments may account for this apparent discrepancy. These issues should be investigated in future studies. In the subgroup analysis stratified by age group, the *IL4RA* Q551R polymorphism was associated with increased pediatric asthma risk. These results demonstrate that even the same variant in the same gene may have a different effect on the pathogenesis and occurrence of asthma in different individuals. To the best of our knowledge, no previous study has assessed the age-specific influence of *IL4RA* Q551R on asthma risk, and further studies are needed to address the effect of this polymorphism on asthma risk in different age groups. We also carried out a subgroup analysis according to atopic status. There was a significant association between this polymorphism and atopic asthma risk, suggesting that the *IL4RA* Q551R polymorphism may play a role in the etiology of atopic asthma. IgE-mediated immune responses are best known for their involvement in allergies. Cornejo-García et al. [@pone.0069120-CornejoGarca1] showed that the *IL4RA* Q551R polymorphism was associated with IgE against prevalent allergens and with total IgE. The *IL4RA* Q551R polymorphism may therefore be a relevant marker for allergies and atopic asthma development.

IL-4Rα has been shown to play a pivotal role in the pathogenesis of Th2 inflammation and asthma. For example, Kelly-Welch et al. [@pone.0069120-KellyWelch1] reported that IL-4Rα-deficient mice engrafted with bone marrow derived from IL-4Rα-expressing mice failed to develop goblet-cell metaplasia in response to allergic airway inflammation. In addition, deletion of the gene encoding IL-4Rα rendered mice resistant to the induction of experimental allergic asthma [@pone.0069120-Grnig1]. Mitsuyasu et al. [@pone.0069120-Mitsuyasu1] documented that the IL-4Rα 50I variant significantly upregulated the receptor response to IL-4, with resultant increased activation of STAT6, and hence increased cell proliferation and increased IgE production. Furthermore, Rosenwasser et al. [@pone.0069120-Rosenwasser1] showed that peripheral blood mononuclear cells derived from individuals carrying the 551R variant had enhanced IL-4 responsiveness compared with 551Q. It is therefore possible that these two polymorphisms could influence the susceptibility to asthma. The 50I and 551Q variants may be associated with increased asthma risk. The results of this meta-analysis strongly support this hypothesis.

A previous meta-analysis by Loza and Chang has focused on the relationship between these polymorphisms and asthma risk [@pone.0069120-Loza1], and concluded that the I50 V polymorphism was not significant associated with asthma. However, only six studies of the I50 V polymorphism were included in that meta-analysis. A positive association between this polymorphism and asthma could therefore not be ruled out, because studies with small sample sizes may have had insufficient statistical power to detect any slight effect. Our current meta-analysis included 30 studies (6442 cases and 7240 controls), and found a moderate but significant association. Furthermore, this meta-analysis addressed the methodological issues such as cumulative meta-analysis and sensitivity analysis.

Results from our meta-analysis were stable and reliable. First, sensitivity analyses and cumulative meta-analyses revealed that the results were robust. Second, there was no significant heterogeneity in most of the comparisons. Third, funnel plots and Egger\'s tests found no significant publication bias. However, some limitations should be addressed. First, the numbers of published studies involving African Americans and Mexicans were limited. Second, the overall outcome was based on unadjusted data, whereas a baseline risk-adjusted analysis could be performed if individual data were available to allow adjustment. Third, asthma is a complex disease with multifactorial etiology. A lack of original data from the eligible studies limited evaluation of the effects of the gene-gene and gene-environment interactions during asthma development. These gene-environment and gene-gene interactions should be further evaluated. Fourth, even though no significant publication bias was found by funnel plot analysis and formal statistical tests, it was impossible to exclude potential publication bias completely, because small studies with null results tend not to be published. Finally, all the studies included in this meta-analysis used a case-control design, which was susceptible to recall and selection biases. In addition, there was a risk of residual confounding by unmeasured factors.

In conclusion, this meta-analysis found significant associations between the *IL4RA* I50V and Q551R polymorphisms and asthma risk. Further studies in more ethnic groups, especially African Americans and Mexicans, are warranted to validate these results.
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